Jaguar Health (JAGX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$27.8M

Revenue (quarter)

$1.2M

Revenue growth (year over year)

−58.88%

Gross profit (trailing twelve months)

$22.9M

Gross margin

82.31%

Net income (trailing twelve months)

−$36.9M

Net income (quarter)

−$12.8M

Net income growth (year over year)

−21.23%

Net margin

−132.73%

Return on equity

−717.93%

EPS (trailing twelve months)

−$393.34

Book value per share

$20.43

P/E (trailing twelve months)

—

Price to book

1.81

Debt to assets

85.61%

Payout ratio

—

Dividend yield

—

Company profile

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

• Is Jaguar Health (JAGX) profitable?

  No. Jaguar Health reported a net loss of $36.9M over the trailing twelve months.

• How much revenue does Jaguar Health (JAGX) make?

  Jaguar Health generated $27.8M in revenue over the trailing twelve months, down 58.88% year over year.

• How do I buy stock in Jaguar Health (JAGX)?

  JAGX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.